56
Participants
Start Date
March 31, 2005
Primary Completion Date
July 31, 2010
Study Completion Date
July 31, 2010
NMR-spectroscopy
Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
Oral acamprosate
For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
National Institutes of Health Clinical Center (CC)
NIH